Date: Jul 07, 2021

View Recorded Q&A

"We will present the physician and physicist perspectives of the lessons learnt from 25 years of SBRT including the technical and practice advances, and possible explanations for the 10 times lower complications risk that was observed when averaged over several datasets with Synchrony."

 

Dr. Mahadevan

Anand Mahadevan, M.D., Geisinger Medical Center, Danville, Pennsylvania

After graduating from Madras Medical College in India, Dr. Anand Mahadevan completed his surgical and oncology training in the UK. After a 2-year fellowship in the Harvard Radiation Oncology program, he went on to become a staff radiation oncologist at the Beth Israel Deaconess Medical Center, Harvard Medical School faculty and Assistant Program director of the Harvard Radiation Oncology Program. He is currently the Professor and Chairman of Radiation Oncology at the Geisinger Health System. His clinical interests and contributions are primarily in stereotactic radiation to liver and pancreatic tumors, oligometastasis and neurooncology.

Grimm

Jimm Grimm, Ph.D., Geisinger Medical Center, Danville, Pennsylvania

Dr. Jimm Grimm, is the Lead CyberKnife Physicist at Geisinger.  He has commissioned three CyberKnife systems and provided physics support for thousands of stereotactic body radiation therapy (SBRT) cases.  Dr. Grimm designed the DVH Evaluator, an FDA-cleared software tool that aids with comparing radiation therapy treatment plans to applicable dose tolerance limits, and for recording follow-up patient response and symptoms.  The software has been used in the statistical tumor control probability (TCP) and normal tissue complication probability (NTCP) analysis of data from more than 30,000 SBRT cases for several published clinical datasets including the full April 2016 issue of Seminars in Radiation Oncology on NTCP for SBRT, as well as the May 2021 Special Issue of the Red Journal on HyTEC: High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic.

Dr. Lischalk

Jonathan Lischalk, M.D., NYU CyberKnife Center at the Perlmutter Cancer Center, Manhattan, NY 

Dr. Jonathan Lischalk is a board certified Radiation Oncologist who specializes in the treatment of prostate, lung, and brain/spine cancers. He earned his undergraduate degree in Neuroscience and Biochemistry from the University of Washington and went on to graduate from the University of Washington School of Medicine. He completed his internship in internal medicine at Stamford Hospital /Columbia University College of Physicians and Surgeons and residency training in radiation oncology at Georgetown University Hospital where he served as Chief Resident. Following completion of residency, he was hired as academic faculty at Georgetown University Hospital where he served as Director of Thoracic Radiation Oncology. Today, Dr. Lischalk serves as the Medical Director of the NYU CyberKnife Center at the Perlmutter Cancer Center in Manhattan as well as Assistant Professor and Director of Research for the NYU-LI Department of Radiation Oncology. He is the author of more than 30 peer reviewed publications in a variety of oncologic topics including prostate, lung, and CNS malignancies.